IP Library Granted Patent US 7,915,314
Granted Patent B2
US 7,915,314 · App. 12/642,508 · Granted Mar 29, 2011

Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Assignees: Emisphere Technologies, Inc.; Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,915,314
App. No.
12/642,508
Granted
Mar 29, 2011
Kind
B2
Abstract

The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. The delivery agents have the formula wherein R 1 , R 2 , R 3 , and R 4 are independently hydrogen, halogen, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy; and R 5 is a substituted or unsubstituted C 2 -C 16 alkylene, substituted or unsubstituted C 2 -C 16 alkenylene, substituted or unsubstituted C 1 -C 12 alkyl(arylene), or substituted or unsubstituted aryl(C 1 -C 12 alkylene). The hydrates and solvates of present invention also have surprisingly greater efficacy for delivering active agents, such as heparin and calcitonin, than their corresponding monosodium salts and free acids. The present invention provides an alcohol solvate, such as ethanol solvate, of a disodium salt of a delivery agent of the formula above. The invention also provides a hydrate of a disodium salt of a delivery agent of the formula above. Preferred delivery agents include, but are not limited to, N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). The invention also provides methods of preparing the disodium salt, ethanol solvate, and hydrate and compositions containing the disodium salt, ethanol solvate, and/or hydrate.

Claims (8)

1. A solid pharmaceutical composition comprising from about 50% to about 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and (b) a biologically active agent selected from human growth hormone, parathyroid hormone, and a biologically active fragment of parathyroid hormone.

2. The solid pharmaceutical composition of claim 1 , wherein the biologically active agent is human growth hormone.

3. The solid pharmaceutical composition of claim 1 , wherein the biologically active agent is parathyroid hormone or a biologically active fragment thereof.

4. The solid pharmaceutical composition of claim 1 , wherein the composition comprises from about 90% to about 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and the biologically active agent is human growth hormone.

5. The solid pharmaceutical composition of claim 1 , wherein the composition comprises from about 90% to about 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and the biologically active agent is parathyroid hormone or a biologically active fragment thereof.

6. The solid pharmaceutical composition of claim 4 , wherein the composition comprises from about 96% to 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition.

7. The solid pharmaceutical composition of claim 5 , wherein the composition comprises at least from about 96% to 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition.

8. A solid pharmaceutical composition comprising at least from about 96% to 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and (b) a biologically active agent selected from calcitonin, human growth hormone, parathyroid hormone, and a biologically active fragment of parathyroid hormone.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →
Continuity (8)
Continuation 12111750 · Apr 29, 2008
Continuation 10615213 · Jul 7, 2003
Continuation 09962794
Provisional Application 60127754 · Apr 5, 1999
Provisional Application 60186143 · Mar 1, 2000
Provisional Application 60186142 · Mar 1, 2000
Provisional Application 60191286 · Mar 21, 2000
Related Publication 20100099621A1 · Apr 22, 2010